PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDocetaxel
Taxotere(docetaxel)
Beizray, Docetaxel, Docivyx, Taxotere (docetaxel) is a small molecule pharmaceutical. Docetaxel was first approved as Taxotere on 1995-11-27. It is used to treat breast neoplasms, head and neck neoplasms, melanoma, non-small-cell lung carcinoma, and ovarian neoplasms amongst others in the USA. It has been approved in Europe to treat adenocarcinoma, adenoma, breast neoplasms, head and neck neoplasms, and non-small-cell lung carcinoma amongst others. The pharmaceutical is active against tubulin beta chain.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
Trade Name
FDA
EMA
Docetaxel, Taxotere (discontinued: Docetaxel, Taxotere)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Docetaxel
Tradename
Company
Number
Date
Products
DOCETAXELAccord HealthcareN-201195 RX2012-04-20
3 products, RLD, RS
DOCETAXELAllerganN-203551 RX2013-04-12
4 products
DOCETAXELHospiraN-022234 RX2011-03-08
6 products, RLD, RS
DOCETAXELSandozN-201525 RX2011-06-29
3 products
TAXOTERESanofiN-020449 RX2012-04-13
1 products, RLD
DOCETAXELShilpa MedicareN-205934 RX2015-12-22
3 products, RLD, RS
Show 8 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
beizrayNew Drug Application2025-09-15
beizray beizrayNew Drug Application2025-09-16
docetaxelANDA2025-09-09
docetaxel anhydrousANDA2023-07-10
docivyxNew Drug Application2025-07-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
prostatic neoplasms—D011471C61
breast neoplasmsEFO_0003869D001943C50
ovarian neoplasmsEFO_0003893D010051C56
pancreatic neoplasmsEFO_0003860D010190C25
non-small-cell lung carcinoma—D002289—
stomach neoplasmsEFO_0003897D013274C16
head and neck neoplasms—D006258—
melanoma—D008545—
soft tissue neoplasms—D012983—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Docetaxel, Docetaxel, Avyxa Holdings
103987852036-03-14DP
Docetaxel, Docetaxel, Shilpa
89407862033-09-30DPU-1789
93081952033-09-30DP
97638802033-09-30U-2558, U-2559, U-2560, U-2561, U-2562, U-2563, U-2564
108427702031-08-07DPU-2998
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01C: Plant alkaloids and other natural products, antineoplastic drugs
— L01CD: Taxanes, antineoplastic
— L01CD02: Docetaxel
HCPCS
Code
Description
J9171
Injection, docetaxel, 1 mg
Clinical
Clinical Trials
3004 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeutropeniaD009503—D70—12——2
Chemotherapy-induced febrile neutropeniaD064146———12——2
Prostatic neoplasmsD011471—C61——2——2
Castration-resistant prostatic neoplasmsD064129————1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDocetaxel
INNdocetaxel
Description
Docetaxel anhydrous is a tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group. It has a role as an antineoplastic agent, a photosensitizing agent and an antimalarial. It is a tetracyclic diterpenoid and a secondary alpha-hydroxy ketone. It derives from a hydride of a taxane.
Classification
Small molecule
Drug classantineoplastics, taxane derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O
Identifiers
PDB—
CAS-ID148408-66-6
RxCUI—
ChEMBL IDCHEMBL3545252
ChEBI ID59809
PubChem CID148124
DrugBankDB01248
UNII ID699121PHCA (ChemIDplus, GSRS)
Target
Agency Approved
TUBB
TUBB
Organism
Homo sapiens
Gene name
TUBB
Gene synonyms
TUBB5
NCBI Gene ID
203068
Protein name
tubulin beta chain
Protein synonyms
beta Ib tubulin, epididymis secretory sperm binding protein, tubulin beta-1 chain, Tubulin beta-5 chain, tubulin, beta polypeptide
Uniprot ID
Q9CY33
Mouse ortholog
Tubb5 (22154)
tubulin beta-5 chain (Q3UF52)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Docetaxel – Eagle Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Docetaxel
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 645 documents
View more details
Safety
Black-box Warning
Black-box warning for: Beizray, Beizray beizray, Docetaxel, Docetaxel anhydrous, Docivyx
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
89,539 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use